Unranked

Enveric Biosciences, Inc.

ENVB

$1.8991

-3.11% (24h)

Last updated: 1 second ago

Market Cap

$6.99M

Volume (24h)

30.26K

Last Close (7D)

$1.90

View on TradingView

Price Chart

Company Profile

Sector

Healthcare

Industry

Biotechnology

Employees

Website

www.enveric.com

Country

🇺🇸 United States

A clinical-stage biotech developing novel psychedelic- and cannabinoid-inspired neurological medicines, with a pipeline aimed at anxiety, depression, and cancer-related psychological distress.

🧠 Next-generation psychedelic compounds designed for improved precision versus first-generation psilocybin or MDMA

Key Stats

52-Week Range

$1.71$17.64

Beta1.10

Trailing P/EN/A

Forward P/E-1.35

Trailing EPS-22.74

Avg Volume3.8M

Enterprise Value$2.31M

Shares Outstanding3.68M

Earnings & Analyst

Next EarningsN/A

EPS EstimateN/A

Target Mean PriceN/A

RecommendationNone

Recommendation MeanN/A

Latest News

Benzinga · Jun 2, 2026
Enveric Biosciences Initiates Investigational New Drug-enabling Genotoxicity Studies Of EB-003
Benzinga · May 15, 2026
Enveric Biosciences Q1 EPS $(1.08) Up From $(14.64) YoY
Finnhub · May 15, 2026
Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026
Finnhub · May 13, 2026
Enveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders